BACKGROUND AND AIMS: Studies suggest that stroke patients with thrombus in a major cerebral vessel respond less favorably to intravenous (IV) thrombolysis. The purpose of this study was to test the feasibility of a protocol comparing IV versus intra-arterial (IA) recombinant tissue plasminogen activator (TPA) in an acute ischemic stroke with major vessel occlusion. METHODS:Consecutive ischemic stroke patients presenting <3 h from symptom onset with major vessel occlusion on CT angiogram (CTA) were randomly assigned to IV TPA (per NINDS protocol) or IA TPA (22 mg over 2 h). Demographics, times to presentation and thrombolysis, presenting NIH stroke scale (NIHSS) and 90-day NIHSS, Barthel Index, and modified Rankin Scale were recorded. CT-scans at 24-h were reviewed for presence of hemorrhage. Recanalization was determined by post-procedure MR angiograms, which are obtained the day after thrombolytic therapy. RESULTS:Seven patients (median NIHSS = 16) were randomized to IV (N = 4) or IA (N = 3) TPA. There were no significant differences in the presentation NIHSS, time to presentation, or time to treatment between the two groups. Hemorrhage was noted in one patient in the IA group (asymptomatic) and one patient in the IV group (symptomatic). Recanalization was seen in all patients treated with IA TPA and none treated with IV TPA (P = 0.03, Fisher's Exact test). CONCLUSIONS: We found that it is feasible to conduct a trial comparing IV vs. IA TPA in ischemic stroke patients with major vessel occlusion presenting <3 h from onset. Patients treated with IA TPA showed a trend toward higher rate of recanalization. A larger trial may be designed to test safety and effectiveness of IA TPA in this specific group of stroke patients.
RCT Entities:
BACKGROUND AND AIMS: Studies suggest that strokepatients with thrombus in a major cerebral vessel respond less favorably to intravenous (IV) thrombolysis. The purpose of this study was to test the feasibility of a protocol comparing IV versus intra-arterial (IA) recombinant tissue plasminogen activator (TPA) in an acute ischemic stroke with major vessel occlusion. METHODS: Consecutive ischemic strokepatients presenting <3 h from symptom onset with major vessel occlusion on CT angiogram (CTA) were randomly assigned to IV TPA (per NINDS protocol) or IA TPA (22 mg over 2 h). Demographics, times to presentation and thrombolysis, presenting NIH stroke scale (NIHSS) and 90-day NIHSS, Barthel Index, and modified Rankin Scale were recorded. CT-scans at 24-h were reviewed for presence of hemorrhage. Recanalization was determined by post-procedure MR angiograms, which are obtained the day after thrombolytic therapy. RESULTS: Seven patients (median NIHSS = 16) were randomized to IV (N = 4) or IA (N = 3) TPA. There were no significant differences in the presentation NIHSS, time to presentation, or time to treatment between the two groups. Hemorrhage was noted in one patient in the IA group (asymptomatic) and one patient in the IV group (symptomatic). Recanalization was seen in all patients treated with IA TPA and none treated with IV TPA (P = 0.03, Fisher's Exact test). CONCLUSIONS: We found that it is feasible to conduct a trial comparing IV vs. IA TPA in ischemic strokepatients with major vessel occlusion presenting <3 h from onset. Patients treated with IA TPA showed a trend toward higher rate of recanalization. A larger trial may be designed to test safety and effectiveness of IA TPA in this specific group of strokepatients.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: T Neumann-Haefelin; R du Mesnil de Rochemont; J B Fiebach; A Gass; C Nolte; T Kucinski; J Rother; M Siebler; O C Singer; K Szabo; A Villringer; P D Schellinger Journal: Stroke Date: 2003-12-11 Impact factor: 7.914
Authors: Heinrich P Mattle; Marcel Arnold; Dimitrios Georgiadis; Christian Baumann; Krassen Nedeltchev; David Benninger; Luca Remonda; Christian von Büdingen; Anca Diana; Athina Pangalu; Gerhard Schroth; Ralf W Baumgartner Journal: Stroke Date: 2007-12-20 Impact factor: 7.914
Authors: R Christian Crumrine; Victor J Marder; G McLeod Taylor; Joseph C Lamanna; Constantinos P Tsipis; Philip Scuderi; Stephen R Petteway; Vikram Arora Journal: Exp Transl Stroke Med Date: 2011-09-20
Authors: Lisa E Thomas; Joshua N Goldstein; Reza Hakimelahi; Yuchiao Chang; Albert J Yoo; Lee H Schwamm; R Gilberto Gonzalez Journal: Int J Emerg Med Date: 2011-10-03
Authors: Ali S Arbab; Christine Thiffault; Bradford Navia; Stephen J Victor; Klaudyne Hong; Li Zhang; Quan Jiang; Nadimpalli Rs Varma; Asm Iskander; Michael Chopp Journal: BMC Med Imaging Date: 2012-12-06 Impact factor: 1.930